Novel therapies in breast cancer: what is new from ASCO 2008
2008
Novel Therapies in Breast Cancer from ASCO 2008
Sample size: 126
publication
10 minutes
Evidence: moderate
Author Information
Author(s): David Chu, Janice Lu
Primary Institution: State University of New York at Stony Brook
Conclusion
Recent advances in targeted therapies have improved treatment options for metastatic breast cancer.
Supporting Evidence
- Lapatinib showed a 40% overall response rate in HER2 positive relapsed/refractory inflammatory breast cancer.
- Combination therapies involving bevacizumab and chemotherapy demonstrated improved progression-free survival.
- New agents like HKI-272 and trastuzumab DM-1 are being investigated for their efficacy in advanced breast cancer.
Takeaway
Doctors are finding new ways to treat breast cancer that are less harmful and more effective than older methods.
Methodology
This review summarizes novel therapies presented at the ASCO 2008 meeting, focusing on targeted and biologic therapies for breast cancer.
Limitations
The review is based on presentations and may not include all data from ongoing studies.
Participant Demographics
The review discusses various studies involving patients with metastatic breast cancer, including those with HER2 positive and triple-negative breast cancer.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website